CA2307030A1 - Derives d'isoquinoline substitues et leur utilisation en tant qu'anticonvulsifs - Google Patents

Derives d'isoquinoline substitues et leur utilisation en tant qu'anticonvulsifs Download PDF

Info

Publication number
CA2307030A1
CA2307030A1 CA002307030A CA2307030A CA2307030A1 CA 2307030 A1 CA2307030 A1 CA 2307030A1 CA 002307030 A CA002307030 A CA 002307030A CA 2307030 A CA2307030 A CA 2307030A CA 2307030 A1 CA2307030 A1 CA 2307030A1
Authority
CA
Canada
Prior art keywords
hydrogen
4alkyl
disorders
methyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002307030A
Other languages
English (en)
Inventor
Mervyn Thompson
John David Harling
Peter David Edwards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9722537.9A external-priority patent/GB9722537D0/en
Priority claimed from GBGB9726663.9A external-priority patent/GB9726663D0/en
Application filed by Individual filed Critical Individual
Publication of CA2307030A1 publication Critical patent/CA2307030A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

De nouveaux composés de formule (I) sont utiles dans la prophylaxie et le traitement de l'anxiété, des troubles de manie(s), de la dépression, des troubles de panique et/ou d'agression, des troubles associés à une hémorragie sous-arachnoïdienne ou à un choc neuronal, des effets associés au sevrage de substances nocives telles que la cocaïne, la nicotine, l'alcool et les benzodiazépines, des troubles pouvant être traités et/ou prévenus avec des agents anticonvulsivants tels que l'épilepsie y compris l'épilepsie post-traumatique, la maladie de Parkinson, la psychose, la migraine, l'ischémie cérébrale, la maladie d'Alzheimer et d'autres maladies dégénératives telles que la chorée de Huntingdon, la schizophrénie, les troubles obsessionnels-compulsifs (TOC), les déficits neurologiques associés au SIDA, les troubles du sommeil (y compris les dérèglements du rythme circadien, l'insomnie et la narcolepsie ), les tics ( par exemple la maladie de Gilles de La Tourette ), les lésions traumatiques du cerveau, le tinnitus, la névralgie, la névralgie essentielle du trijumeau, les douleurs neuropathiques, les douleurs dentaires, les douleurs cancéreuses, l'activité neuronale inappropriée entraînant des neurodysthésies dans des maladies telles que le diabète, la sclérose en plaques (SP) et la maladie du motoneurone, les ataxies, la rigidité musculaire (spasticité), la dysfonction de l'articulation temporo-mandibulaire et la sclérose latérale amyotrophique (SLA) .
CA002307030A 1997-10-24 1998-10-22 Derives d'isoquinoline substitues et leur utilisation en tant qu'anticonvulsifs Abandoned CA2307030A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9722537.9A GB9722537D0 (en) 1997-10-24 1997-10-24 Novel compounds
GB9722537.9 1997-10-24
GB9726663.9 1997-12-17
GBGB9726663.9A GB9726663D0 (en) 1997-12-17 1997-12-17 Novel compounds
PCT/GB1998/003165 WO1999021836A1 (fr) 1997-10-24 1998-10-22 Derives d'isoquinoline substitues et leur utilisation en tant qu'anticonvulsifs

Publications (1)

Publication Number Publication Date
CA2307030A1 true CA2307030A1 (fr) 1999-05-06

Family

ID=26312489

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002307030A Abandoned CA2307030A1 (fr) 1997-10-24 1998-10-22 Derives d'isoquinoline substitues et leur utilisation en tant qu'anticonvulsifs

Country Status (4)

Country Link
EP (1) EP1025087A1 (fr)
JP (1) JP2001521026A (fr)
CA (1) CA2307030A1 (fr)
WO (1) WO1999021836A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915589D0 (en) * 1999-07-02 1999-09-01 Smithkline Beecham Plc Novel compounds
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2003245773A1 (en) * 2002-02-15 2003-09-04 Glaxo Group Limited Vanilloid receptor modulators
GB0210762D0 (en) * 2002-05-10 2002-06-19 Glaxo Group Ltd Compounds
JP4334204B2 (ja) 2002-11-21 2009-09-30 メルク株式会社 高輝度高彩度虹彩顔料およびその製造方法
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DK2001474T3 (en) * 2006-03-16 2016-05-09 Second Genome Inc BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF
TWI464148B (zh) * 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
JP2010520875A (ja) 2007-03-09 2010-06-17 レノビス， インコーポレイテッド Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用
ES3029867T3 (en) * 2019-12-18 2025-06-25 Chdi Foundation Inc Compounds and probes for imaging huntingtin protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674791A (en) * 1968-03-26 1972-07-04 Marion Laboratories Inc Benzamido 2 lower alkyl decahydroisoquinolines
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
JPS4824396B1 (fr) * 1970-09-09 1973-07-20
EP0912493A1 (fr) * 1996-06-19 1999-05-06 The Procter & Gamble Company Procede d'elimination des mauvaises odeurs se degageant de polyamines modifiees
CA2284218A1 (fr) * 1997-03-18 1998-09-24 Smithkline Beecham P.L.C. Derives d'isoquinoline substituee et leur utilisation en tant qu'anticonvulsivants

Also Published As

Publication number Publication date
WO1999021836A1 (fr) 1999-05-06
EP1025087A1 (fr) 2000-08-09
JP2001521026A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
AU729124B2 (en) Substituted benzamide derivatives and their use as anticonvulsants
NZ337424A (en) Substituted isoquinoline derivatives and their use as anticonvulsants and in the treatment and/or prophylaxis of other neurological disorders
WO2000007993A1 (fr) Isoquinoleines substituees et leur utilisation en tant qu'anticonvulsifs
CA2307030A1 (fr) Derives d'isoquinoline substitues et leur utilisation en tant qu'anticonvulsifs
AU744451B2 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
US6274594B1 (en) Isoquinoline derivatives and their therapeutical use
US6277861B1 (en) Anti-convulsant isoquinolyl-benzamide derivatives
AU762716B2 (en) Novel compounds
WO1999052857A1 (fr) Nouveaux composes
US20010025045A1 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
US6762192B2 (en) Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity

Legal Events

Date Code Title Description
FZDE Dead